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The non-linear inverse relationship between RR-intervals and heart rate (HR) contributes
significantly to the heart rate variability (HRV) parameters and their performance in
mortality prediction. To determine the level of influence HR exerts over HRV parameters’
prognostic power, we studied the predictive performance for different HR levels by
applying eight correction procedures, multiplying or dividing HRV parameters by the mean
RR-interval (RRavg) to the power 0.5–16. Data collected from 1288 patients in The Finnish
Cardiovascular Study (FINCAVAS), who satisfied the inclusion criteria, was used for the
analyses. HRV parameters (RMSSD, VLF Power and LF Power) were calculated from
2-min segment in the rest phase before exercise and 2-min recovery period immediately
after peak exercise. Area under the receiver operating characteristic curve (AUC) was
used to determine the predictive performance for each parameter with and without HR
corrections in rest and recovery phases. The division of HRV parameters by segment’s
RRavg to the power 2 (HRVDIV-2) showed the highest predictive performance under
the rest phase (RMSSD: 0.67/0.66; VLF Power: 0.70/0.62; LF Power: 0.79/0.65; cardiac
mortality/non-cardiac mortality) with minimum correlation to HR (r = −0.15 to 0.15). In
the recovery phase, Kaplan-Meier (KM) survival analysis revealed good risk stratification
capacity at HRVDIV -2 in both groups (cardiac and non-cardiac mortality). Although higher
powers of correction (HRVDIV-4and HRVDIV-8) improved predictive performance during
recovery, they induced an increased positive correlation to HR. Thus, we inferred that
predictive capacity of HRV during rest and recovery is augmented when its dependence
on HR is weakened by applying appropriate correction procedures.
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INTRODUCTION
Heart rate (HR) recovery and heart rate variability (HRV) have
been used by researchers for assessing the role of autonomic
regulation in predicting all-cause and cardiovascular mortality
(Freeman et al., 2006). The prognostic capabilities of HR response
to exercise and after exercise have been well-documented (Lauer
et al., 1996; Cole et al., 1999; Lipinski et al., 2004; Jouven et al.,
2005; Kiviniemi et al., 2011) and reviewed by Freeman et al.
(2006). Increased sympathetic and decreased parasympathetic
activities have been associated with an enhanced risk of sudden
death or the vulnerability to ventricular arrhythmias (Lahiri et al.,
2008). Subdued time- and frequency-domain HRV indices have
been linked with increased risk of mortality in the Framingham
cohort (Tsuji et al., 1994), survivors of acute myocardial infarc-
tion (MI) (Kleiger et al., 1990; Kiviniemi et al., 2007) and cardio-
vascularmorbidity andmortality (Zuanetti et al., 1996). However,
studies determining the prognostic capacity of exercise induced
short-term HRV have been sparse and inconsistent. Leino et al.
(2010) concluded that none of the HRV indices were good predic-
tors ofmortality during peak exercise or recovery phase. In a study
by Dewey et al. (2007), a greater short-term HRV during recovery
post exercise was associated with an increased risk for all-cause
and cardiovascular mortality. This is in contrast to observations
made in resting HRV, which implies higher RR-interval variabil-
ity is associated with better prognosis (Dekker et al., 2000; Leino
et al., 2010).
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Nieminen et al. (2007) justified that the non-linear inverse
relationship between RR interval and HR could be the cause for
misinterpretation when comparing subjects with different HR
levels and this has been concurred by other researchers (Chiu
et al., 2003; Sacha and Pluta, 2005; Sacha et al., 2005; Virtanen
et al., 2007; Bailón et al., 2011). Possible physiological mech-
anisms involved have also been probed (Perini and Veicteinas,
2003; Goldberger et al., 2006). The non-linear relation between
HR and HRV has been addressed by Sacha and Pluta (2008)
and correction methods have been suggested to strengthen or
weaken the influence of HR (Sacha et al., 2013a; Sacha, 2013). By
determining whether decreasing dependence on HR improves the
prognostic capacity of HRV, we sought to establish the influence
of HR in predicting mortality risk. The aim of our study was to
scrutinize these correction techniques and their influence on the
predictive capacity of cardiac and non-cardiac mortality in the
Finnish Cardiovascular Study (FINCAVAS) cohort.
MATERIALS AND METHODS
PATIENT POPULATION AND FOLLOW-UP
A total of 2212 consecutive patients, who were referred by a physi-
cian and willing to undergo exercise stress tests at the Tampere
University Hospital, were recruited between 2001 and 2004 for
FINCAVAS. Informed consent was obtained from all the par-
ticipants prior to the interview. Measurements were conducted
as stipulated in the Declaration of Helsinki and the study pro-
tocol was approved by the Ethical Committee of the Hospital
District of Pirkanmaa, Finland. In addition to raw electrocar-
diograph (ECG), descriptive information, medical history and
habitual lifestyle of each patient were recorded. More detailed
information regarding the patient population and sample size
determination is described elsewhere (Nieminen et al., 2006). Of
these, 1288 patients satisfied the inclusion criteria for this study
with good quality HRV measurements for at least 2min dur-
ing rest phase, immediately prior to exercise, and 2min during
post-exercise recovery immediately after maximum effort.
The follow-up data consisted of information related to causes
of death and was collected in 2011. The information for the
follow-up was obtained from Causes of Death Register and has
been shown to be reliable (Pajunen et al., 2005). The follow-up
yielded 66 cardiac deaths and 94 non-cardiac deaths, while the
remaining 1128 patients constituted the survival group.
EXERCISE TESTING PROTOCOL
The prognoses of mortality were analyzed using HRV indices
obtained from 2min segments during rest phase before exercise
and 2min recovery immediately after maximal exercise. Resting
ECG was measured in the supine position prior to exercise. The
exercise stress test was then performed on a bicycle ergometer
with electrical brakes and the Mason-Likar modified lead system
Table 1 | Baseline characteristics of the study population, classified into survival, cardiac, and non-cardiac mortality groups.
Survival group (N = 1128) Mortality group (N = 160)
Cardiac mortality (N = 66) Non-cardiac mortality (N = 94) p-value
INDIVIDUAL FACTORS
Age (years) 54.3±12.6 61.6±10.9 64.1±10.5 0.145
Gender (males, %) 699 (62.0) 42 (78.8) 58 (61.7) 0.020
BMI 27.4±4.5 28.9±4.7 27.0±3.9 0.004
Smoking (yes, %) 317 (28.1) 20 (30.3) 32 (34.0) 0.622
CRI (%) 82.8±24.4 62.3±30.1 73.5±29.8 0.021
Resting heart rate (bpm) 63.3±11.3 64.8±13.9 64.5±12.5 0.656
SAP at rest (mmHg) 135.8±18.5 134.4±21.1 136.3±20.2 0.563
DAP at rest (mmHg) 79.7±9.6 78.1±9.9 77.3±12.2 0.675
Maximum heart rate (bpm) 149.1±25.7 125.6±27.2 132.1±26.5 0.106
SAP peak exercise (mmHg) 196.2±28.6 179.7±32.9 184.8±27.8 0.296
DAP peak exercise (mmHg) 92.4±12.3 88.2±12.2 87.7±13.4 0.813
CLINICAL CONDITION
CHD (yes, %) 360 (31.9) 30 (45.5) 32 (34.0) 0.146
MI (yes, %) 226 (20.0) 24 (36.4) 22 (23.4) 0.075
Diabetes (yes, %) 128 (11.3) 15 (22.7) 14 (14.9) 0.208
MEDICATION
ACE inhibitors (yes, %) 235 (20.8) 26 (39.4) 21 (22.3) 0.020
Beta blockers (yes, %) 639 (56.6) 56 (84.8) 70 (74.5) 0.116
Calcium channel blockers (yes, %) 179 (15.9) 17 (25.8) 19 (20.2) 0.412
Diuretics (yes, %) 180 (16.0) 20 (30.3) 28 (29.8) 0.945
Lipid medication (yes, %) 443 (39.3) 39 (59.1) 44 (46.8) 0.127
Nitrates (yes, %) 357 (31.6) 32 (48.5) 44 (46.8) 0.208
Values are expressed as Mean ± SD or number of subjects (%). BMI, body mass index; CRI, chronotropic response index; SAP, systolic arterial pressure; DAP,
diastolic arterial pressure; CHD, coronary heart disease; MI, myocardial infarction.
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(Mason and Likar, 1966) was used for the ECG data acquisi-
tion. Initial work load and increments were defined based on
patient’s age, gender, body mass index (BMI) and physical activ-
ity. Starting work load varied between 20 and 30W and the
stepwise increments ranged between 10 and 30W every minute.
ECG and HR were measured continuously during the test. Tests
were sign- and symptom-limited with the recommended criteria
for termination whereas in the case of post-MI patients, the
upper limit for HR was set at 120–130 beats per minute (bpm).
The chronotropic response index (CRI), which represents the
chronotropic response to exercise, was evaluated as CRI = 100 ×
(peak HR − resting HR)/(220 − age − resting HR) (Kiviniemi
et al., 2011). CRI < 80% was defined as low reserve capacity
(Lauer et al., 1996). Measurement during the recovery phase was
performed in the sitting position, immediately after exercise.
HRV MEASUREMENT
ECG was recorded at a sampling frequency of 500Hz using
CardioSoft exercise ECG system (Version 4.14, GE Healthcare,
Freiburg, Germany) and was analyzed using Modified CASE soft-
ware (GE Healthcare, Freiburg, Germany). After producing the
RR-interval tachogram, the data was preprocessed to remove
abnormal intervals and artifacts before they were divided into
shorter segments based on the stages of rest and recovery. HRV
parameters were determined using the Kubios HRV analysis soft-
ware (Tarvainen et al., 2014). All intervals were resampled using
cubic spline interpolation at 4Hz. Linear and smoothness prior
(smoothing parameter, λ = 500) detrending were performed
prior to calculating time-domain parameters. The fast Fourier
transform (FFT) spectrum was computed with a window width
of 240 samples, which corresponds to the length of 1min segment
with 4Hz resampling rate. A 50% overlapping window was used
for longer segments. Mean RR intervals (RRavg) were calculated
from each segment individually for the HR correction procedure.
Post-exercise recovery is marked by sympathetic withdrawal
and parasympathetic reactivation. Sympathetic activation and
attenuated parasympathetic recovery are significantly associated
with adverse prognosis. The parameters included for examina-
tion were chosen based on previous HRV studies on mortality
prediction and its outcomes. Of the spectral measures, low fre-
quency (0.04–0.15Hz, LF) power has been found to increase
during exercise in normal subjects and reflects both sympathetic
and vagal influences (Malliani et al., 1991). In addition, higher log
LF power during recovery significantly predicted increased risk
of all-cause and cardiovascular mortality (Dewey et al., 2007).
Bigger et al. (1993) demonstrated that spectral measures from
short segments (2–15min) correlated significantly with those
computed using 24-h periods. Bernardi et al. (1996) indicated
that very low frequency (0.0033–0.04Hz, VLF) power fluctu-
ations were highly dependent on changes in physical activity,
rather than preconceived notion of reflecting autonomic tone and
thereby, emphasized the importance of activity as a confounding
factor. Therefore, VLF power was evaluated due to its indepen-
dent risk stratification property for all-cause mortality in patients
Table 2 | Association of individual factors, clinical conditions and medication to cardiac and non-cardiac mortality based on univariate Cox
regression.
Cardiac mortality (N = 66) Non-cardiac mortality (N = 94)
RR (95% CI) p-value RR (95% CI) p-value
INDIVIDUAL FACTORS
Age ≥ 60 years 2.33 (1.43–3.80) < 0.001 3.01 (1.98–4.58) < 0.001
Gender (male) 2.27 (1.26–4.09) < 0.05 0.98 (0.65–1.48) 0.91
BMI ≥ 25 1.40 (0.76–2.56) 0.001 1.08 (0.68–1.73) 0.47
Smoking (yes) 1.10 (0.65–1.85) 0.13 1.29 (0.84–1.98) 0.21
CRI ≤ 80% 3.95 (2.25–6.93) < 0.001 2.02 (1.33–3.08) < 0.001
CRI ≤ 39% 4.98 (2.76–8.99) < 0.001 2.63 (1.43–4.82) < 0.001
HRrest ≥ 80 bpm 0.59 (0.32–1.06) 0.08 0.70 (0.44–1.17) 0.13
HRmax ≤ 120 bpm 3.69 (2.27–6.00) < 0.001 2.12 (1.37–3.27) < 0.001
CLINICAL CONDITIONS
CHD (yes) 1.72 (1.06–2.78) < 0.05 1.05 (0.68–1.60) 0.84
MI (yes) 2.18 (1.32–3.60) < 0.001 1.16 (0.72–1.86) 0.55
Diabetes (yes) 2.16 (1.21–3.84) < 0.05 1.29 (0.73–2.27) 0.38
MEDICATION
ACE inhibitors (yes) 2.37 (1.45–3.89) < 0.001 1.06 (0.65–1.73) 0.81
Beta blockers (yes) 3.95 (2.02–7.75) < 0.001 2.03 (1.28–3.23) < 0.05
Calcium channel blockers (yes) 1.76 (1.01–3.05) < 0.05 1.29 (0.78–2.13) 0.33
Diuretics (yes) 2.09 (1.24–3.54) < 0.05 2.09 (1.34–3.25) < 0.05
Lipid medication (yes) 2.11 (1.29–3.45) < 0.05 1.29 (0.86–1.93) 0.22
Nitrates (yes) 1.87 (1.16–3.03) < 0.05 1.70 (1.13–2.55) < 0.05
CI, confidence interval; RR, relative risk; BMI, body mass index; CRI, chronotropic response index; HRrest , resting heart rate; HRmax , maximum heart rate achieved
during peak exercise; CHD, coronary heart disease; MI, myocardial infarction.
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FIGURE 1 | Predictive performance of heart rate variability (HRV)
parameters for: (A) cardiac mortality and (B) non-cardiac mortality
groups. Area under the receiver operating characteristics curves (AUC) and
correlation coefficients (r), between HRV parameters and HR, for different
correction methods during rest and recovery after exercise. AUC > 0.5
indicates that higher heart rate variability (HRV) is associated with better
prognosis and AUC < 0.5 indicates higher HRV is associated with worse
prognosis.
with acute MI (Bigger et al., 1993). Although high frequency
(0.15–0.4Hz, HF) power has been frequently used to measure
parasympathetic tone in resting HRV, interpreting values dur-
ing recovery after exercise is complicated due to tonic autonomic
activity and residual adrenergic activity (Dewey et al., 2007).
Goldberger et al. (2006) demonstrated that short-term (as small
as 30 s windows) root mean squared difference of successive RR
intervals (RMSSD), which represents high frequency variations
in HR, is adequate for measuring parasympathetic reactivation in
recovery phase.
HR CORRECTION
As described by Sacha et al. (2013a), the HRV dependence on
HR is strengthened or weakened by multiplying or dividing
the HRV indices by the corresponding segment’s RRavg, respec-
tively. In addition to normal determination of HRV indices,
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eight other classes for the indices were assessed in this study:
HRVMUL-0.5—multiplying HRV indices by RRavg to the power
0.5; HRVMUL-2—multiplying HRV indices by RRavg to the power
2; HRVMUL-4—multiplying HRV indices by RRavg to the power 4;
HRVDIV-0.5—dividing HRV indices by RRavg to the power 0.5;
HRVDIV-2—dividing HRV indices by RRavg to the power 2;
HRVDIV-4—dividing HRV indices by RRavg to the power 4;
HRVDIV-8—dividing HRV indices by RRavg to the power 8; and
HRVDIV-16—dividing HRV indices by RRavg to the power 16.
With these classes, different levels of dependence/independence
to HR were attained and can be considered significant in deter-
mining the contribution of HR in prognosis of cardiac and
non-cardiac mortalities.
STATISTICAL ANALYSES
The relative risks for cardiac and non-cardiac mortality were
assessed for individual characteristics, clinical condition and
medication using univariate Cox models. The measure of the
predictive power for different HR correction methods for each
segment was computed using area under the receiver operat-
ing characteristics (ROC) curve. Spearman’s rank correlation
was performed to determine the degree of correspondence to
HR. The cut-off points for Kaplan-Meier (KM) survival analy-
ses were defined from the ROC analyses for each segment. The
point of highest overall predictive performance (average of sen-
sitivity and specificity) was chosen as the cut-off to distinguish
mortality and survival groups based on HRV observed in the
patient population. It has to be noted that these cut-off points
were not optimized in order to preserve uniformity during com-
parisons. The Log-rank chi-square estimates were then used to
evaluate the significance of the correction methods based on this
classification.
RESULTS
During the follow-up of the patients who satisfied the inclusion
criteria, 66 cardiac deaths were recorded, which included 31 sud-
den cardiac deaths, with a mean follow-up time of 54 months
(min: 4.8 days; max: 99.5 months). 94 patients died of non-
cardiovascular causes between 1.2 and 110.7 months of follow-up
(mean: 60.2 months). The baseline characteristics, clinical condi-
tions and medications used by patients who suffered cardiac and
non-cardiac deaths are listed in Table 1.
The univariate Cox regression results for various factors asso-
ciated with cardiac and non-cardiac mortality are presented in
Table 2. The relative risk (RR) of cardiac death was significantly
higher in males [RR = 2.27, 95% confidence interval (CI) =
1.26–4.09, p < 0.05]. Age ≥ 60 years was a risk factor for cardiac
(RR = 2.33, 95% CI = 1.43–3.80, p < 0.001) and non-cardiac
(RR = 3.01, 95% CI = 1.98–4.58, p < 0.001) mortality. Clinical
conditions were significantly associated with risk of cardiac death.
Medication such as ACE inhibitors (RR = 2.37, 95% CI = 1.45–
3.89) and beta blockers (RR = 3.95, 95% CI = 2.02–7.75) were
significantly associated with increased risk of cardiac mortality
(p < 0.001).
The area under the ROC curve (AUC) for HR was found to
be 0.57/0.70 (rest/recovery) for cardiac mortality and 0.53/0.64
for non-cardiac mortality, implying that HR is a better predictor
during recovery than during rest phase. The AUC for RMSSD,
VLF and LF power, calculated under different correction methods
during rest and recovery phases are presented in Figures 1A,B.
Correlation with HR (r, presented in Figure 1) indicated increas-
ing dependence or independence of HRV to HR, based on the
method of correction used. AUC > 0.5 suggested that higher
HRV are indicative of better prognosis. HRVDIV-2, which revealed
minimum correlation to HR, was the best predictor for both
outcomes (cardiac and non-cardiac mortality) in the rest phase.
However, during recovery, higher standard HRV (i.e., HRV with-
out correction) was associated with worse prognosis (AUC <
0.5), as seen in Figure 1. In addition, similar associations were
observed for HRV parameters multiplied by different powers
of RRavg (HRVMUL-0.5, HRVMUL-2, and HRVMUL-4). Conversely,
after division by higher powers of RRavg (i.e., for HRVDIV-2,
HRVDIV-4, HRVDIV-8, and HRVDIV-16), higher HRV was associ-
ated with better prognosis (AUC> 0.5). Though higher orders of
correction resulted in better predictive capacity, it also induced
moderate/strong positive correlation to HR (in the case of
HRVDIV-4, HRVDIV-8, and HRVDIV-16).
These results were further corroborated by KM survival anal-
ysis. Log-rank estimates at different degrees of correction for
both cardiac and non-cardiac mortality are presented in Table 3.
HRVMUL-4 andHRVDIV-16 were excluded due to their very strong
correlation to HR. Mortality prediction was most significant for
HRVDIV-2 in the rest phase. During recovery, the division of
HRV by higher powers of RRavg resulted in better risk stratifica-
tion for cardiac and non-cardiac deaths. Although HRVDIV-4 and
HRVDIV-8 exhibited better predictive powers during recovery, the
HRV indices exhibited strong positive correlation to HR (r = 0.6
Table 3 | Chi-square values for Kaplan-Meier analyses under different
heart rate correction methods for cardiac and non-cardiac mortality.
Parameter HRVMUL-2 Without HRVDIV-2 HRVDIV-4 HRVDIV-8
correction
CARDIAC MORTALITY
Two minute resting period prior to exercise
RMSSD 14.10** 11.36** 43.47** 25.22** 11.37**
VLF power 9.90* 21.43** 27.56** 27.84** 15.56**
LF power 33.84** 61.65** 75.37** 50.60** 25.38**
Two minute recovery period post exercise
RMSSD 15.88** 7.93** 16.98** 30.77** 35.84**
VLF power 13.56** 4.81** 21.38** 48.48** 42.57**
LF power 5.50* 12.72** 20.09** 41.77** 52.71**
NON-CARDIAC MORTALITY
Two minute resting period prior to exercise
RMSSD 8.97* 16.82** 26.64** 21.46** 10.09**
VLF power 7.63* 15.54** 19.16** 19.05** 10.44**
LF power 16.17** 21.24** 24.13** 17.73** 12.46**
Two minute recovery period post exercise
RMSSD 18.60** 7.83* 4.59* 16.09** 21.21**
VLF power 9.56* 3.95* 5.08* 19.22** 29.24**
LF power 4.43* 2.49 8.61* 28.39** 26.01**
Significance is denoted by *p < 0.05 and **p < 0.001.
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FIGURE 2 | Kaplan-Meier (KM) survival curves for prediction of
cardiac mortality using heart rate variability (HRV) parameters at
rest and recovery after exercise. Curves in gray represent HRV
indices without correction and in black indicate the survival estimates
for the best correction with minimum dependence on heart rate
(HRVDIV-2).
Frontiers in Physiology | Clinical and Translational Physiology June 2014 | Volume 5 | Article 208 | 6
Pradhapan et al. Heart rate correction on HRV
FIGURE 3 | Kaplan-Meier (KM) survival curves for prediction of
non-cardiac mortality using heart rate variability (HRV) parameters
at rest and recovery after exercise. Curves in gray represent HRV
indices without correction and in black indicate the survival estimates
for the best correction with minimum dependence on heart rate
(HRVDIV-2).
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to 0.9 across both groups, as shown in Figure 1) at these correc-
tion levels. On the contrary, HRVDIV-2 was a good predictor of
cardiac (p < 0.001) and non-cardiac (p < 0.05) mortality during
recovery, with minimum influence of HR (r = −0.15 to 0.15).
Figures 2, 3 represent the survival curves for HRVDIV-2 during
rest and recovery.
DISCUSSION
The HRV indices computed from RR-interval measurements cor-
related with HR as a result of the non-linear relationship between
the RR-interval and instantaneous HR (Chiu et al., 2003; Sacha
and Pluta, 2005; Sacha et al., 2005; Nieminen et al., 2007; Virtanen
et al., 2007; Bailón et al., 2011). Higher variability during rest
and lower variability during recovery were associated with better
prognosis, and this corresponds to observations made by Dewey
et al. (2007). Our results indicate that the predictive capacity of
HRV at rest was highest when the correlation to HR was mini-
mum (HRVDIV-2, r = −0.15 to 0.15), suggesting that exclusion
of HR influence on resting HRV improved prognostic capac-
ity for cardiac and non-cardiac mortality. Since HR is a poor
predictor at rest, removal of HR influence perchance resulted
in improved prognostic capacity. On the contrary, HR during
recovery phase exhibited significant risk stratification for both
outcomes. Thus, increasing HRV’s dependence on HR enhanced
its predictive capacity (observed in HRVDIV-4 and HRVDIV-8).
However, higher degrees of correction produced moderate/strong
positive correlation to HR, similar to observations made by Sacha
et al. (2013c), Sacha (2014). To attain true independence, the cor-
rection technique that yields HRV least influenced by HR, needs
to be identified. In our study, HRVDIV-2 demonstrated improve-
ment in predictability of mortality risk during recovery phase
with minimum dependence on HR.
However, conclusive evidence could not be established to dis-
tinguish between cardiac and non-cardiac related deaths. This is
in contrast to findings by Sacha et al. (2013b), who suggested that
increasing the HRV dependence on HR resulted in greater pre-
dictive ability for cardiac death and increasing its independence
indicated greater predictive power for non-cardiac death. One
possible explanation could be that the study population analyzed
by Sacha and coworkers comprised only post-MI patients whereas
the current study included more heterogeneous patient material.
This study suffered certain limitations. First, the risk factors
for individual, clinical conditions and medication were not mod-
eled to determine their contribution toward mortality prediction.
By including these variables to the analyses, a more definite con-
clusion on the cause of mortality could have been established.
Second, the patients were not controlled for the type of medica-
tion prescribed. The effects of beta blockers and nitrates have been
known to affect HR, which could have an effect on the results of
HR correction. However, the purpose of the current study was to
evaluate the effects of HR correction methods in mortality pre-
diction and therefore, these issues need to be considered in future
studies.
CONCLUSION
The findings of this study indicate that the predictive power of
HRV parameters for both cardiac and non-cardiac mortality is
augmented when its dependence on HR is weakened during rest
and recovery. In addition, whenHR is a good predictor, increasing
HRV’s dependence on HR further enhances the risk stratification
for both modes of death.
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